NCT06734884View on ClinicalTrials.gov

Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 6, 2025

Primary Completion Date

January 5, 2029

Study Completion Date

September 1, 2029

Conditions
DRESS Syndrome
Interventions
DRUG

Benralizumab 30 MG/ML [Fasenra]

Subcutaneous injection 30 mg at day 2, week 4 and week 8.

DRUG

Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride

Subcutaneous injection at day 2, week 4 and week 8

Trial Locations (1)

59000

Delphine STAUMONT-SALLE, Lille

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University Hospital, Lille

OTHER